- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06467708
Transcutaneous Auricular Neurostimulation for ICU Patients With Traumatic Brain Injury (tAN-TBI)
Delivering Transcutaneous Auricular Neurostimulation (tAN) to ICU Patients With Traumatic Brain Injury (tAN-TBI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single-center, open-label, nonrandomized investigation. TBI patients with a post resuscitation Glasgow Coma Scale (GCS) score of 12 or less (commonly described as moderate or severe TBI) and acute traumatic intradural blood on head CT scan will be screened upon admission to the ICU at Parkland Memorial Hospital. It is expected that all or almost all subjects will be in the Neuroscience or Surgical ICU. Consent for participation will be sought from the subject's legally authorized representative. Exception from informed consent or waiver of consent will not be part of this study.
tAN will begin as soon as feasible after subject enrollment. Immediately prior to this intervention, vital signs, neurologic status, and other clinical parameters will be recorded, and pre-tAN blood will be collected for measurement of serum inflammatory markers. tAN will be administered for 30 minutes under the supervision of a member of the research team. After 30 minutes (just prior to stopping tAN), the same clinical parameters that were recorded at baseline will again be recorded then tAN will be stopped. Approximately two hours after tAN has ended, a post-tAN blood sample will be collected for measurement of the same inflammatory markers as in the pre-tAN blood sample. At each timepoint for blood collection, additional blood may be collected for banking and future analyses.
Patients will undergo research blood draws and tAN stimulation for a maximum of 10 days. Research-related procedures will not exceed this 10-day period.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alex Valadka, MD
- Phone Number: 2146452300
- Email: alex.valadka@utsouthwestern.edu
Study Contact Backup
- Name: Aisha Qureshi
- Phone Number: 2146489905
- Email: Aisha.Qureshi@UTSouthwestern.edu
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Post-resuscitation GCS score 12 or below and acute trauma-related intradural blood on head CT scan after TB
- Age 18 years or older (pediatric trauma patients are not routinely transported to Parkland)
- Consent from legally authorized representative
Exclusion Criteria:
- Hemodynamic instability
- Expected imminent mortality because of overwhelming neurological and/or systemic injury
- Unclear neurological status because of paralytic medications or intoxication with ethanol or other drugs
- Presence of other electrical stimulation devices (pacemaker, cochlear prosthesis, neurostimulator, etc.)
- Abnormal ear anatomy or ear infection
- Participant is pregnant or lactating
- Any other significant medical or psychosocial problems that, in the opinion of the investigator, would potentially cause harm to the participant, impact their ability to participate, or influence the results of the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Determine the effect of tAN on serum concentrations of inflammatory mediators in TBI patients
Subjects will receive treatment upon providing informed consent and will undergo transcutaneous auricular neurostimulation (tAN) once daily during their ICU stay, with the treatment duration not exceeding 10 days.
Two blood samples will be collected daily: one before the tAN session and another two hours after the session.
Participant data will be collected daily throughout the ICU stay.
Additionally, surveys will be collected from registered nurses providing direct care to TBI patients enrolled in the tAN-TBI study to assess the compatibility of tAN with patient care processes in the ICU.
|
This method of simultaneous vagal and trigeminal stimulation via the external ear is known as transcutaneous auricular neurostimulation (tAN), as the targets of electrical stimulation include the auricular branch of the vagus nerve (ABVN) and auriculotemporal nerve (ATN), which is a branch of the mandibular division of the trigeminal nerve.
Electrodes applied to select dermatome regions can target ear neural structures and deliver non-invasive vagus nerve stimulation (VNS) and trigeminal nerve stimulation (TNS).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survey nursing attitudes towards daily tAN and the compatibility of tAN with standard patient care activities in the ICU; Examine the safety of tAN in ICU patients.
Time Frame: Registered nurses can complete the Sparrow Ascent ICU User Acceptance Questionnaire at Day 1- Day 10, or before the TBI patient is discharged from the hospital, or ICU. It may not be completed on Day 11 or after the patient has been discharged.
|
Registered nurses providing direct care to ICU patients receiving tAN will be asked to complete the Sparrow Ascent ICU User Acceptance Questionnaire to assess the compatibility of tAN with patient care.
|
Registered nurses can complete the Sparrow Ascent ICU User Acceptance Questionnaire at Day 1- Day 10, or before the TBI patient is discharged from the hospital, or ICU. It may not be completed on Day 11 or after the patient has been discharged.
|
Determine the effect of tAN on serum concentrations of inflammatory mediators in TBI patients.
Time Frame: TBI patients will receive tAN stimulation once per day and will not exceed 10 days.
|
Every effort will be made to initiate tAN as soon after injury as possible in order to capture early postinjury data on the effectiveness of tAN and to inform the design of future studies.
|
TBI patients will receive tAN stimulation once per day and will not exceed 10 days.
|
Explore the effect of tAN on Blood Pressure
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Blood pressure (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Heart Rate
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Heart rate (bpm) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Respiratory Rate (and ventilator settings and use of noninvasive oxygenation and ventilation if applicable)
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Respiratory rate (bpm) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Temperature
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Temperature (°C/°F) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Intracranial pressure
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Intracranial pressure (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Brain Tissue Oxygen Tension (PbtO2)
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Brain Tissue Oxygen Tension (mmHg) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Glasgow Coma Scale (GCS) (and any sedatives or analgesics that could affect neurological assessment)
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
GCS (and any sedatives or analgesics that could affect neurological assessment) will be checked twice daily, pre-tAN and 30 minutes post-tAN.
Scale from 3 to 15, where 3 represents deep unconsciousness and 15 indicates full consciousness.
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Pupillary Diameter
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Pupillary Diameter (mm) will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Explore the effect of tAN on Neurological Pupil index (NPi) via pupillometry
Time Frame: Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Neurological Pupil index (NPi) via pupillometry dimensionless index, typically ranging from 0 to 5.
This will be checked twice daily, pre-tAN and 30 minutes post-tAN
|
Data will be collected upon consent, twice daily from Day 1 to Day 10, or until the patient is discharged from the hospital. Data will not be collected past 10 days.
|
Collaborators and Investigators
Investigators
- Principal Investigator: Alex Valadka, MD, UT Southwestern Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STU-2024-0360
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on TBI (Traumatic Brain Injury)
-
Sheba Medical CenterRecruitingTraumatic Brain Injury (TBI) PatientsIsrael
-
ElMindA LtdAthletico Physical TherapyCompletedMinor Traumatic Brain Injury (TBI)United States
-
ElMindA LtdNoran Neurological ClinicCompletedHealthy | Minor Traumatic Brain Injury (TBI)United States
-
ElMindA LtdYork UniversityCompletedMinor Traumatic Brain Injury (TBI)Canada
-
University of Texas Southwestern Medical CenterAlbert Einstein College of Medicine; National Institute of Neurological Disorders... and other collaboratorsRecruitingTBI (Traumatic Brain Injury) | TBI | Traumatic Brain Injury With Loss of Consciousness | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateUnited States
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
University of MinnesotaNot yet recruitingTBI (Traumatic Brain Injury)United States
-
Kent State UniversityVirginia Commonwealth UniversityRecruitingTBI (Traumatic Brain Injury)United States
-
Pomeranian Medical University SzczecinCompletedTBI (Traumatic Brain Injury)Poland
-
San Francisco Veterans Affairs Medical CenterVA Office of Research and DevelopmentCompletedTBI (Traumatic Brain Injury)United States
Clinical Trials on Sparrow Ascent Transcutaneous Auricular Neurostimulation (tAN)
-
University of Texas Southwestern Medical CenterNot yet recruitingPain, Postoperative | Opioid Use | Lumbar Spine InjuryUnited States
-
The University of Texas Medical Branch, GalvestonNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingUnderstanding the Effects of Transcutaneous Auricular Neurostimulation for Treatment of Chronic PainAnalgesia | Opioid WithdrawalUnited States
-
University of CincinnatiSpark Biomedical, Inc.RecruitingOpioid Use Disorder | Posttraumatic Stress DisorderUnited States
-
Spark Biomedical, Inc.CompletedOpioid-use Disorder | Opioid WithdrawalUnited States
-
Medical University of South CarolinaRecruiting
-
Spark Biomedical, Inc.Medical University of South CarolinaCompleted
-
Medical University of South CarolinaRecruitingHypermobile Ehlers-Danlos Syndrome | Ehlers-Danlos Syndrome | Hypermobile Spectrum DisorderUnited States
-
Medical University of South CarolinaRecruiting